Genetics of Rolandic Epilepsy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00282854|
Recruitment Status : Unknown
Verified August 2011 by King's College London.
Recruitment status was: Recruiting
First Posted : January 27, 2006
Last Update Posted : December 6, 2011
|Condition or disease|
Rolandic epilepsy (RE) is the most common type of childhood epilepsy-affecting more than 50,000 children in the United States-and has a complex genetic inheritance. The seizure prognosis is relatively benign, however, many children with RE also have problems with speech and language, reading, and motor coordination. Symptoms of the disorder overlap with more severe types of epilepsy.
The purpose of this study is to find the genes that influence RE and its related traits. Identifying genetic causes for the variants would improve diagnosis and allow for early intervention.
Researchers will enroll 1000 children with RE and 3000 controls for participation in the study. The scientists will request medical histories and (salivary) DNA samples from the participants. Participation can be completed by mail and telephone.
Results from this study should provide important information regarding diagnosis and prognosis of RE, may be useful in clinical management, and, eventually, may lead to a cure for this and other forms of epilepsy.
|Study Type :||Observational|
|Estimated Enrollment :||1000 participants|
|Official Title:||Genetics of Rolandic Epilepsy|
|Study Start Date :||January 2005|
|Estimated Primary Completion Date :||December 2013|
|Estimated Study Completion Date :||December 2013|
Group I: Cases
Children with rolandic epilepsy
Group II: Controls
Individuals group matched to cases for ethnicity, sex and area of residence but lacking a primary brain disorder.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00282854
|Contact: Deb Pal, MD, PhD||212 342 firstname.lastname@example.org|
|United States, New York|
|Mailman School of Public Health, Columbia University Medical Center, 722 West 168th St, 6th Floor||Recruiting|
|New York, New York, United States, 10032|
|Contact: Deb Pal, MD, PhD 212-342-1237 email@example.com|
|Principal Investigator:||Deb K. Pal, MD, PhD||Associate Research Scientist, Mailman School of Public Health, Columbia University Medical Center|